ES2351701T3 - USO DE ß-CRIPTOXANTINA. - Google Patents

USO DE ß-CRIPTOXANTINA. Download PDF

Info

Publication number
ES2351701T3
ES2351701T3 ES05738192T ES05738192T ES2351701T3 ES 2351701 T3 ES2351701 T3 ES 2351701T3 ES 05738192 T ES05738192 T ES 05738192T ES 05738192 T ES05738192 T ES 05738192T ES 2351701 T3 ES2351701 T3 ES 2351701T3
Authority
ES
Spain
Prior art keywords
cryptoxanthin
promote
protein
increased protein
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05738192T
Other languages
English (en)
Spanish (es)
Inventor
Karin Wertz
Regina Goralczyk
Adrian Wyss
Anne Eichinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Application granted granted Critical
Publication of ES2351701T3 publication Critical patent/ES2351701T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
ES05738192T 2004-05-18 2005-05-10 USO DE ß-CRIPTOXANTINA. Expired - Lifetime ES2351701T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011743 2004-05-18
EP04011743 2004-05-18

Publications (1)

Publication Number Publication Date
ES2351701T3 true ES2351701T3 (es) 2011-02-09

Family

ID=34966671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05738192T Expired - Lifetime ES2351701T3 (es) 2004-05-18 2005-05-10 USO DE ß-CRIPTOXANTINA.

Country Status (9)

Country Link
US (1) US20080070980A1 (enExample)
EP (1) EP1748705B1 (enExample)
JP (2) JP5145035B2 (enExample)
KR (1) KR101317976B1 (enExample)
CN (1) CN1953669B (enExample)
AT (1) ATE484201T1 (enExample)
DE (1) DE602005024128D1 (enExample)
ES (1) ES2351701T3 (enExample)
WO (1) WO2005110122A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258111A1 (en) * 2006-07-28 2009-10-15 Katsuhiko Takayanagi Highly bioavailable oral administration composition of cryptoxanthin
US20090118227A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
JP5688697B2 (ja) * 2009-09-25 2015-03-25 国立大学法人愛媛大学 免疫蛋白質の産生促進剤
JP5909084B2 (ja) * 2010-12-15 2016-04-26 アークレイ株式会社 安定化βクリプトキサンチン含有水およびその用途
CN102219721B (zh) * 2011-04-02 2013-08-07 秦皇岛大惠生物技术有限公司 一种含有β-隐黄质的浓缩物的提取方法与采用该方法所得到的浓缩物及其用途
CA2841411C (en) * 2011-07-13 2017-09-12 University Of Georgia Research Foundation, Inc. Use of xanthophyll carotenoids to improve visual performance and neural efficiency
MX367861B (es) * 2012-10-04 2019-09-09 Abbott Lab Una composición nutricional para usarse en la preservación del músculo esquelético.
JP5687682B2 (ja) * 2012-12-20 2015-03-18 ユニチカ株式会社 カルシウム吸収促進組成物
CN105073711A (zh) 2013-01-24 2015-11-18 欧米尼艾克蒂夫健康技术有限公司 植物来源的β-隐黄素和其制备方法
US20160106776A1 (en) * 2013-05-31 2016-04-21 Dsm Ip Assets B.V. Feed supplement and its use
MX394164B (es) * 2015-01-15 2025-03-24 Dsm Ip Assets Bv COMBINACION DE 25-HIDROXIVITAMINA D Y ANTIINFLAMATORIO PARA NIVELES SOSTENIDOS DE 17-ß ESTRADIOL EN PLASMA.
US10568846B2 (en) 2015-04-27 2020-02-25 Omniactive Health Technologies Limited Betacryptoxanthin compositions, processes for preparation and uses thereof
CN104906112B (zh) * 2015-05-20 2018-02-23 杨克西 一种促进蛋白质合成的组合物及其制备方法和用途
JP2019218316A (ja) * 2018-06-21 2019-12-26 公立大学法人大阪 オートファジー活性向上剤
SG10201900604TA (en) 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Pre-natal beta-cryptoxanthin benefits children
WO2022018161A1 (en) 2020-07-22 2022-01-27 Dsm Ip Assets B.V. Beta-cryptoxanthin crystal forms, liquid formulations thereof and processes for their manufacture
WO2022018162A1 (en) 2020-07-22 2022-01-27 Dsm Ip Assets B.V. FORMULATIONS OF NEW β-CRYPTOXANTHIN CRYSTAL FORM, PROCESSES FOR THEIR MANUFACTURE AND THEIR USES
CN115530381A (zh) * 2022-08-17 2022-12-30 中南大学 预防产前抑郁症的蛋白粉及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
US8148431B2 (en) * 2002-10-25 2012-04-03 Kemin Health, L.C. Osteogenesis promoter containing β-cryptoxanthin as the active ingredient

Also Published As

Publication number Publication date
DE602005024128D1 (de) 2010-11-25
KR20070011515A (ko) 2007-01-24
KR101317976B1 (ko) 2013-10-14
US20080070980A1 (en) 2008-03-20
EP1748705A1 (en) 2007-02-07
JP2013047227A (ja) 2013-03-07
JP2008500376A (ja) 2008-01-10
ATE484201T1 (de) 2010-10-15
EP1748705B1 (en) 2010-10-13
JP5145035B2 (ja) 2013-02-13
CN1953669A (zh) 2007-04-25
CN1953669B (zh) 2010-06-16
WO2005110122A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
KR101317976B1 (ko) 베타-크립토잔틴의 용도
KR101700016B1 (ko) 근위축 억제제
JP2005501061A (ja) 免疫機能損傷患者の為の栄養療法
US20060039998A1 (en) Remedies
US20120309716A1 (en) Motor Function Improver
KR20240088908A (ko) Ampk 활성화제, 운동 기능 향상제, 근지구력 향상제 및 근위축 억제제
WO2004075905A1 (ja) 筋肉増強剤および筋肉減衰の予防または治療剤
ES2765238T3 (es) Agente promotor de la producción de IGF-1
CN108135955A (zh) 肌肉增强剂
JP6716330B2 (ja) ウロプラキン発現促進剤
Jiang et al. Denatonium as a bitter taste receptor agonist damages jejunal epithelial cells of yellow-feathered chickens via inducing apoptosis
KR101728094B1 (ko) 개머루덩굴 추출물 또는 이의 분획물을 유효성분으로 포함하는 바이러스성 질환 및 암의 예방 또는 치료용 약학적 조성물
JP6117963B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
CN113853211A (zh) 包含环(组氨酸-脯氨酸)二肽及甲状旁腺激素的组合物用于预防、改善或治疗骨质流失疾病的用途
JP5909173B2 (ja) ポリアミンを有効成分とする、組織の再生を促進するための組成物
US12357605B2 (en) Muscle building agent
KR20090064449A (ko) 신규한 기능식품용 및 약학적 조성물 및 관절 내 연골 분해 또는 연골 손상의 치료, 공동치료 또는 예방을 위한 이의 용도
KR101629642B1 (ko) 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
KR20250169452A (ko) 펜노게닌 3-O-β-차코트리오사이드를 유효성분으로 포함하는 대사성 질환의 예방, 개선 또는 치료용 조성물
HK40060507A (en) Use of composition for preventing, ameliorating, or treating bone loss disorders, comprising cyclo-hispro (chp) and parathyroid hormone
JP2008222632A (ja) 関節炎改善剤
JP2012077007A (ja) 持久力向上剤
JP2013100272A (ja) Ｓｒｆシグナル活性化剤